SCHEMBL20489232

SCHEMBL20489232

CCOC(=O)c1[nH]nc(C)c1Cc1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
AR P10275 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
KDM4E B2RXH2 5/20 0.43
LMNA P02545 4/20 0.43
HPGD P15428 2/20 0.43
MAPT P10636 2/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.40
PKM P14618 1/20 0.39
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
GLA P06280 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20488966 0.87 LMNA (0.50) ALDH1A1SMN1; SMN2NPSR1ARMEN1
SCHEMBL20488236 0.84 MAPT (0.38) ALDH1A1SMN1; SMN2NPSR1RXFP1AR
SCHEMBL8188646 0.84 AR (0.51) ALDH1A1SMN1; SMN2NPSR1ARMEN1
SCHEMBL7828097 0.82 LMNA (0.50) ALDH1A1NPSR1RXFP1ARMEN1
SCHEMBL6418611 0.82 AR (0.49) ALDH1A1SMN1; SMN2NPSR1ARMEN1
SCHEMBL5025427 0.81 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2NPSR1ARMEN1
SCHEMBL20489234 0.80 LMNA (0.56) ALDH1A1SMN1; SMN2ARMEN1KMT2A
SCHEMBL28347814 0.75 LMNA (0.40) ALDH1A1SMN1; SMN2ARMEN1KMT2A
SCHEMBL28355831 0.72 L3MBTL1 (0.72) ALDH1A1SMN1; SMN2NPSR1RXFP1L3MBTL1
SCHEMBL20489145 0.72 MEN1 (0.50) MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
WO-2018157190-A9 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-10-25 WO disclosed
WO-2018157190-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF LOX, DAO, AADAC ALDH1A1 301/4885SMN1; SMN2 4781/4885NPSR1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.